(Q35119593)

6 August 2017

1 reference

title

Familial hypercholesterolemia--improving treatment and meeting guidelines (English)

1 reference

6 August 2017

Familial hypercholesterolemia—Improving treatment and meeting guidelines (English)

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

Cardiology and cardiovascular medicine

29 December 2023

main subject

hypercholesterolemia

0 references

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

29 December 2023

author name string

Paul N. Hopkins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12727001

29 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12727001

29 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0167527302004205?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

https://api.elsevier.com/content/article/PII:S0167527302004205?httpAccept=text/plain

29 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

International Journal of Cardiology

29 December 2023

published in

1 reference

6 August 2017

volume

89

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

13-23

1 reference

An update on familial hypercholesterolaemia

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

The LDL receptor gene: a mosaic of exons shared with different proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Homozygous familial hypercholesterolemia among French Canadians in Québec Province

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

A new locus for autosomal recessive hypercholesterolemia maps to human chromosome 15q25-q26

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Experiences with the Homozygous Cases of Familial Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Importance of diet in the treatment of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Effects of n-3 and n-6 fatty acid-enriched diets on plasma lipoproteins and apolipoproteins in heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Mechanism of action of bile acid sequestrants and other lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

The effect of cholestyramine on the faecal excretion of bile acids and neutral steroids in familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Clinical efficacy of fluvastatin in thelong-term treatment of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Current perspectives on statins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Withdrawal of cerivastatin from the world market

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

How effective is drug therapy in heterozygous familial hypercholesterolemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900420-5

7 January 2021

The LDL receptor

1

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism

29 December 2023

37

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

29 December 2023

41

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

Discontinuation rates of cholesterol-lowering medications: implications for primary care

29 December 2023

62

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

Experience with plasma-exchange in homozygous familial hypercholesterolaemia

29 December 2023

66

1 reference

https://api.crossref.org/works/10.1016/S0167-5273(02)00420-5

29 December 2023

Identifiers

1 reference

6 August 2017

1 reference